NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

RPRX

Royalty Pharma plc

Jun 30 • 04:00PM ET

36.03

Dollar change +0.16
Percentage change 0.45	%

Healthcare • Biotechnology • USA • NASD

Peers: BIIB REGN VRTX GILD INCY ALNY EXEL NBIX MDGL DKNG

| Held by: VTI VO VXF VFLO VTV VOE IWR VYM VHT SCHM

Scroll to Statements

Index	-	P/E	14.69	EPS (ttm)	2.45	Insider Own	21.15%	Shs Outstand	425.59M	Perf Week	1.78%
Market Cap	20.26B	Forward P/E	7.20	EPS next Y	5.00	Insider Trans	0.00%	Shs Float	332.23M	Perf Month	10.39%
Enterprise Value	29.88B	PEG	1.35	EPS next Q	1.04	Inst Own	77.21%	Short Float	8.74%	Perf Quarter	14.85%
Income	1.09B	P/S	8.95	EPS this Y	6.72%	Inst Trans	-0.17%	Short Ratio	5.59	Perf Half Y	42.81%
Sales	2.26B	P/B	2.29	EPS next Y	13.55%	ROA	6.48%	Short Interest	29.03M	Perf YTD	41.24%
Book/sh	15.72	P/C	18.42	EPS next 5Y	10.87%	ROE	16.57%	52W High	36.32 -0.80%	Perf Year	35.55%
Cash/sh	1.96	P/FCF	7.35	EPS past 3/5Y	8.57% -21.51%	ROIC	8.21%	52W Low	24.05 49.81%	Perf 3Y	-12.29%
Dividend Est.	0.91 (2.54%)	EV/EBITDA	15.73	Sales past 3/5Y	-0.38% 4.52%	Gross Margin	-	Volatility	2.08% 1.89%	Perf 5Y	-29.28%
Dividend TTM	0.86 (2.39%)	EV/Sales	13.20	EPS Y/Y TTM	37.75%	Oper. Margin	83.91%	ATR (14)	0.69	Perf 10Y	-
Dividend Ex-Date	May 16, 2025	Quick Ratio	1.56	Sales Y/Y TTM	1.15%	Profit Margin	48.24%	RSI (14)	64.80	Recom	1.57
Dividend Gr. 3/5Y	7.30% -	Current Ratio	1.56	EPS Q/Q	5042.45%	SMA20	4.03%	Beta	0.49	Target Price	42.17
Payout	43.94%	Debt/Eq	1.14	Sales Q/Q	0.05%	SMA50	7.58%	Rel Volume	0.69	Prev Close	35.87
Employees	99	LT Debt/Eq	0.99	Earnings	May 08 BMO	SMA200	19.23%	Avg Volume	5.19M	Price	36.03
IPO	Jun 16, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-56.79% 18.95%	Trades		Volume	3,582,896	Change	0.45%

Date	Action	Analyst	Rating Change	Price Target Change
May-16-25	Initiated	Morgan Stanley	Overweight	$51
Jun-03-24	Downgrade	UBS	Buy → Neutral	$28
Jun-14-22	Resumed	UBS	Buy	$47
May-13-22	Initiated	Scotiabank	Sector Outperform	$53
Apr-27-22	Initiated	Goldman	Buy	$56
Apr-14-22	Upgrade	JP Morgan	Neutral → Overweight	$50
Apr-06-22	Resumed	Morgan Stanley	Overweight	$48
Oct-29-21	Upgrade	Citigroup	Neutral → Buy	$50
Jul-30-21	Initiated	Tigress Financial	Buy	$50
Nov-09-20	Upgrade	UBS	Neutral → Buy	$52 → $51
Jul-14-20	Initiated	Evercore ISI	In-line
Jul-13-20	Initiated	UBS	Neutral	$52
Jul-13-20	Initiated	SunTrust	Buy	$56
Jul-13-20	Initiated	Morgan Stanley	Equal-Weight	$51
Jul-13-20	Initiated	JP Morgan	Neutral	$50
Jul-13-20	Initiated	Goldman	Neutral	$47
Jul-13-20	Initiated	Cowen	Outperform	$55
Jul-13-20	Initiated	Citigroup	Neutral	$50
Jul-13-20	Initiated	BofA Securities	Buy	$55

Show Previous Ratings

Jun-27-25 08:33AM	5 Revealing Analyst Questions From Royalty Pharma's Q1 Earnings Call (StockStory)
Jun-24-25 07:05AM	Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion (GlobeNewswire)
Jun-18-25 11:39PM	Q1 Rundown: Royalty Pharma (NASDAQ:RPRX) Vs Other Branded Pharmaceuticals Stocks (StockStory)
Jun-12-25 07:26PM	Analyst Report: Royalty Pharma plc (Morningstar Research)
Jun-09-25 09:54AM	RPRX Q1 Earnings Call: Flat Revenue, Portfolio Expansion, and Capital Return Initiatives (StockStory)
04:15PM	Loading…
Jun-04-25 04:15PM	Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
May-16-25 04:30PM	Royalty Pharma Completes the Acquisition of Its External Manager (GlobeNewswire)
May-13-25 08:15AM	Royalty Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
May-12-25 04:15PM	Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition (GlobeNewswire)
May-08-25 08:03PM	Analyst Report: Royalty Pharma plc (Morningstar Research)
10:30AM	Royalty Pharma (RPRX) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
08:25AM	Royalty Pharma (RPRX) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
07:15AM	Royalty Pharma Reports First Quarter 2025 Results (GlobeNewswire)
May-07-25 12:34PM	Royalty Pharma Q1 2025 Earnings Preview (Seeking Alpha)
May-05-25 09:15AM	Unlocking Q1 Potential of Royalty Pharma (RPRX): Exploring Wall Street Estimates for Key Metrics (Zacks)
10:01AM	Loading…
May-01-25 10:01AM	Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Apr-28-25 06:50PM	Alerus (ALRS) Q1 Earnings and Revenues Top Estimates (Zacks)
Apr-24-25 08:16AM	Royalty Pharma PLC (RPRX) Surged Following an Acquisition Announcement (Insider Monkey)
07:36AM	Thomas: Fragile is the word we agreed on (CNBC TV)
Apr-22-25 12:00PM	Patient Capital Management Q1 2025 Investment Review (Seeking Alpha)
11:20AM	Patient Capital Management Q1 2025 Commentary (Seeking Alpha)
Apr-21-25 04:15PM	Royalty Pharma Declares Second Quarter 2025 Dividend (GlobeNewswire)
Apr-17-25 04:15PM	Royalty Pharma to Announce First Quarter 2025 Financial Results on May 8, 2025 (GlobeNewswire)
Apr-10-25 06:20AM	Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now? (Zacks)
Apr-08-25 04:15PM	Royalty Pharma Appoints Vlad Coric, M.D. to the Company's Board of Directors (GlobeNewswire)
Apr-02-25 09:47AM	Is Royalty Pharma plc (RPRX) The Most Profitable Biotech Stock To Buy Right Now? (Insider Monkey)
Apr-01-25 10:00AM	Is Royalty Pharma Plc (RPRX) the Most Undervalued Healthcare Stock to Buy According to Analysts? (Insider Monkey)
06:20AM	Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)? (Zacks)
Mar-29-25 07:15AM	4 Healthcare Stocks With Massive Gains-and More to Come (MarketBeat)
Mar-27-25 08:15AM	Royalty Pharma Announces Upcoming Investor Day (GlobeNewswire)
11:43AM	Loading…
Mar-26-25 11:43AM	3 Reasons to Sell RPRX and 1 Stock to Buy Instead (StockStory) -6.52%
Mar-25-25 09:19PM	Is Royalty Pharma plc (RPRX) The Best Defensive Stock Amid Market Volatility? (Insider Monkey)
Mar-21-25 11:30AM	Why Is Blue Owl Capital Corporation (OBDC) Down 3% Since Last Earnings Report? (Zacks)
05:12AM	Q4 Earnings Highs And Lows: Royalty Pharma (NASDAQ:RPRX) Vs The Rest Of The Branded Pharmaceuticals Stocks (StockStory)
Feb-27-25 04:15PM	Royalty Pharma to Present at TD Cowen's 45th Annual Health Care Conference (GlobeNewswire)
Feb-23-25 03:03PM	Why Royalty Pharma Plc (RPRX) is the Best Performing Pharma Stock So Far in 2025 (Insider Monkey)
Feb-13-25 07:57PM	Analyst Report: Royalty Pharma plc (Morningstar Research)
Feb-12-25 09:06AM	Analyst Report: Royalty Pharma plc (Morningstar Research)
06:30AM	Royalty Pharma Announces R&D Funding Collaboration With Biogen (GlobeNewswire)
02:07AM	Royalty Pharma PLC (RPRX) Q4 2024 Earnings Call Highlights: Strong Financial Performance and ... (GuruFocus.com)
Feb-11-25 07:33AM	Royalty Pharma (NASDAQ:RPRX) Misses Q4 Revenue Estimates (StockStory)
07:15AM	Royalty Pharma Reports Q4 and Full Year 2024 Results (GlobeNewswire)
Feb-10-25 08:03AM	Royalty Pharma Earnings: What To Look For From RPRX (StockStory)
Jan-29-25 09:00AM	Royalty Pharma Announces Sale of MorphoSys Development Funding Bonds (GlobeNewswire)
Jan-28-25 04:15PM	Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025 (GlobeNewswire)
Jan-23-25 06:29AM	Why Is Andreas Halvorsen Bullish On Royalty Pharma plc (RPRX) Now? (Insider Monkey)
Jan-15-25 01:52PM	Royalty Pharma plc (RPRX): Analysts Recommend This 52-Week High Stocks Now (Insider Monkey)
Jan-12-25 11:24AM	Heres Why Royalty Pharma plc (RPRX) Led This Weeks Rally (Insider Monkey)
Jan-11-25 01:10PM	Did Royalty Pharma (RPRX) Close Shortened Trading Week Higher? (Insider Monkey)
Jan-10-25 07:30AM	Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +12.56%
07:15AM	Royalty Pharma Announces Transformative Step in Company's Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program (GlobeNewswire)
Jan-09-25 04:15PM	Royalty Pharma Announces Dividend Increase (GlobeNewswire)
Dec-27-24 05:47AM	Jim Cramer on Royalty Pharma plc (RPRX): Disappointing Stock, Man, I Cant Believe It (Insider Monkey)
Dec-24-24 04:45AM	Jim Cramer Calls Royalty Pharma (RPRX) Disappointing But Recommends Holding I Want You To Stick With It (Insider Monkey)
Dec-19-24 08:06PM	Lightning Round: MandT Bank is a buy, I like the banks, says Jim Cramer (CNBC TV)
Nov-27-24 04:15PM	Royalty Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
11:11AM	Why Royalty Pharma (RPRX) is the Cheapest Stock to Buy on Robinhood? (Insider Monkey)
Nov-14-24 04:30PM	Royalty Pharma Announces Inaugural Prize for Impact in Healthcare (GlobeNewswire)
Nov-07-24 07:10AM	Royalty Pharma to Acquire Royalty Interest in Geron's RYTELO for $125 Million (GlobeNewswire)
02:10AM	Royalty Pharma PLC (RPRX) Q3 2024 Earnings Call Highlights: Strong Growth and Strategic Acquisitions (GuruFocus.com)
12:08AM	Royalty Pharma PLC (RPRX): A Strategic SWOT Insight (GuruFocus.com)
Nov-06-24 07:16PM	Analyst Report: Royalty Pharma plc (Morningstar Research)
07:15AM	Royalty Pharma Reports Third Quarter 2024 Results (GlobeNewswire)
Nov-04-24 04:15PM	Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo (GlobeNewswire)
04:01PM	Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo (PR Newswire)
Nov-03-24 06:11AM	Morgan Stanley Predicts Up to 670% Jump for These 2 Strong Buy Stocks (TipRanks)
Oct-16-24 04:15PM	Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024 (GlobeNewswire)
Oct-11-24 08:15AM	Royalty Pharma Declares Fourth Quarter 2024 Dividend (GlobeNewswire)
Oct-09-24 05:31PM	Royalty Pharma PLC (RPRX) Q2 2024 Earnings Call Highlights: Surpassing Growth Expectations and ... (GuruFocus.com)
03:50PM	Royalty Pharma plc (RPRX): Among The Stocks With Biggest Upside Potential According to Hedge Funds (Insider Monkey)
Sep-03-24 05:14PM	Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement (GlobeNewswire)
05:06PM	Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement (GlobeNewswire)
Aug-28-24 04:15PM	Royalty Pharma to Present at Morgan Stanley's 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-26-24 06:16AM	Jim Cramer on Royalty Pharma plc (NASDAQ:RPRX): Its Been a Bit of a Bust, I Feel Badly (Insider Monkey)
Aug-23-24 05:32AM	Jim Cramer's Latest Lightning Round: Top 10 Stocks (Insider Monkey)
Aug-17-24 03:58PM	Why Is Royalty Pharma plc (RPRX) the Best Defensive Stock to Buy Now? (Insider Monkey)
Aug-16-24 06:09PM	10 Best Defensive Stocks To Buy Now (Insider Monkey)
Aug-09-24 01:05AM	Royalty Pharma PLC (RPRX): A Strategic SWOT Insight (GuruFocus.com)
Aug-08-24 04:16PM	Analyst Report: Royalty Pharma plc (Morningstar Research)
07:00AM	Royalty Pharma Reports Second Quarter 2024 Results (GlobeNewswire)
Jul-24-24 08:30AM	Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital (GlobeNewswire)
Jul-19-24 08:15AM	Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024 (GlobeNewswire)
Jul-17-24 04:15PM	Royalty Pharma Declares Third Quarter 2024 Dividend (GlobeNewswire)
Jul-15-24 12:10PM	Will Royalty Pharma (RPRX) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Jul-02-24 07:44PM	Is Royalty Pharma plc (RPRX) a Good Stock to Buy Now? (Insider Monkey)
06:58PM	10 Best Undervalued Stocks To Buy Now (Insider Monkey)
Jun-26-24 06:00AM	Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024 (InvestorPlace)
Jun-24-24 12:56PM	7 Biotech Stocks to Buy on the Dip: June 2024 (InvestorPlace)
Jun-05-24 06:14AM	June's Biotech Boom: 3 Stocks to Buy for a Summertime Surge (InvestorPlace)
Jun-04-24 04:15PM	Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
Jun-03-24 05:15PM	Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes (GlobeNewswire)
May-28-24 07:10AM	Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million (GlobeNewswire)
May-27-24 06:28PM	Is Cytokinetics, Incorporated (NASDAQ:CYTK) the Best Mid-Cap Healthcare Stock To Buy Now? (Insider Monkey)
May-25-24 11:10PM	20 Biggest Publicly Traded Biotech Companies (Insider Monkey)
May-22-24 04:10PM	Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline (GlobeNewswire)
04:00PM	Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline (GlobeNewswire)
May-20-24 02:41PM	7 Dividend Stocks to Buy at a 52-Week Low (InvestorPlace)
May-13-24 08:15AM	Royalty Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
May-10-24 01:07AM	Royalty Pharma PLC (RPRX): A Strategic SWOT Insight (GuruFocus.com)
May-09-24 03:35PM	Analyst Report: Royalty Pharma plc (Morningstar Research)

Royalty Pharma Plc engages in the provision of drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RPRX

Royalty Pharma plc

Upgrade your FINVIZ experience